An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

In an apparently unprecedented move, Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of the drug giant’s money.

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence (AI). Traditionally, drug development has been a lengthy, costly, and ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The GLP-1 drug ... Eli Lilly's market share over time. For example, Amgen (AMGN) is developing MariTide and Pfizer (PFE) is developing oral GLP-1 candidates. Again, the similarity to Nvidia in AI ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Let's look at five pharma and drug companies ... at where Eli Lilly and Company (NYSE:LLY) stands against the other dividend stocks. During a time of great excitement about AI-driven capital ...

Jan 15 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Wednesday the U.S. health regulator has approved its drug to treat adults ... Meta CEOs defend hefty AI spending after DeepSeek stuns ...